Introduction
Urolithiasis is one of the most common disorders of theurinary tract affecting about 5%-10% of the population. The increasing prevalence of ureteric stones is a matter of concern in this era, and it may be linked to improved quality of life [1] .
Minimally invasive therapies, such as extracorporeal shock wave lithotripsy and ureterolithotripsy, represent efficacious treatment modalities in almost all cases. Nevertheless, these procedures imply high costs and are not risk free [2] . A watchful waiting approach has been reported to be associated with spontaneous stone expulsion in up to 50% of cases but some complications may occur such as urinary tract infections, hydronephrosis and colic events [2] . The use of a watchful waiting approach has been extended as a result of advances in pharmacological therapy, which can reduce symptoms and facilitate stone expulsion [3, 4] .
Medical expulsive therapy (MET) has now become an established method of treatment, and it involves the use of various drugs acting on the ureter by different mechanisms. The ureter is lined by α 1 -adrenergic receptors, particularly the subtype α 1D , which are found more in its distal third, and they play an important role in the lower ureteric physiology through an effect on detrusor and ureteric smooth muscle contraction [5] . Use of a selective α-adrenoceptor blocker for MET is a cost effective approach to treating ureteral stones, based on the growing body of evidence supporting its efficacy [6, 7] . Both the American Urological Association (AUA) and the European Association of Urology include α-adrenoceptor blockers in their treatment recommendations [7, 8] .
The blocking of these receptors subsequently induces selective relaxation of the ureteric smooth muscle, which will result in ureteric lumen dilatation facilitating antegrade stone propagation [9, 10] . Several studies have shown that tamsulosin, an α 1A/1D -adrenoceptor antagonist, facilitates ureteral stone expulsion [11] [12] [13] [14] . Recently, we reported that α 1A -adrenoceptors are the main participant in phenylephrineinduced ureteral contraction in the human isolated ureter [15] . Therefore, silodosin, a recently introduced selective α 1A -adrenoceptor antagonist, has shown promising results with fewer side effects and a better efficacy [16] .
The goal of the present study was to perform a metaanalysis to evaluate the safety and efficacy of silodosin compared with placebo or tamsulosin in treating ureteral calculi, which may find that silodosin might have potential as MET for ureteral stones.
Methods

Data sources and searches
We carried out an electronic search of Cochrane Library (Issue 4, April 2015), PubMed (1966 to April 2015) and Embase (1974 to April 2015 . The search strategy consisted of three parts (strategies for silodosin, calculi and a specific filter for clinical trials) using the following keywords in combination with both medical subject headings terms and text words: silodosin, ureteral calculi, urolithiasis, medical expulsion therapy, stone and randomized controlled trials. There was no limitation on publication status or language. We also searched the metaRegister and World Health Organization International Clinical Trials Registry Platform for ongoing studies. Reference lists of the included studies were checked manually to identify further studies.
Studies selection
We included randomized controlled trials that compared silodosin vs. placebo or tamsulosin for ureteral calculi. The patients in this study were limited to the population diagnosed with a single, unilateral, symptomatic, ureteric stone of 10 mm or smaller in the largest dimension in the distal ureter visible. The patients were evaluated with plain X-ray, ultrasonography and unenhanced computed tomography (CT) scans whenever they were necessary. The stone size was calculated on the first plain X-ray or CT by using a digital ruler and the greatest dimension of the stone was taken into consideration as the stone size. Studies that examined the use of silodosin in special population groups (people with renal insufficiency, urinary tract infections, high grade hydronephrosis, previous therapies for the stone, solitary kidney, history of ureteral surgery or previous endoscopic procedures, concomitant calcium antagonists or corticosteroids medications, ureteric strictures, cardiovascular diseases, incomplete data) were excluded. The primary outcomes for this study were the stone expulsion rate and complication. The secondary outcomes included the stone expulsion time (days), pain episodes and abnormal ejaculation. Trials were eligible if one of these outcome measures was reported. Study eligibility was independently determined by two authors. The authors evaluated the eligibility of the remaining studies by examining the titles, abstracts and full articles progressively. Discrepancies were resolved by discussion.
Data extraction and quality assessment
Data were extracted independently by two authors using a standard form. Data extracted included study characteristics (title, publication time and patient numbers), patient characteristics (age, the location of the stone and size), intervention, control, method (randomization, blinding and loss to follow-up) and outcomes (estimates, standard error and P value). Discrepancies were resolved by discussion. The authors of original studies were consulted for missing information where necessary.
Both methodological quality and quality of the evidence were assessed independently by two authors.
Efficacy and safety of silodosin for calculi The methodological quality of included studies was appraised with the Cochrane Collaboration bias appraisal tool [17] . Based on the quality assessment criteria, each study was rated and assigned to one of the three following quality categories: A) if all quality criteria were adequately met, the study was deemed to have a low risk of bias, B) if one or more of the quality criteria was only partially met or was unclear, the study was deemed to have a moderate risk of bias or C) if one or more of the criteria were not met, or not included, the study was deemed to have a high risk of bias.
Data synthesis and analysis
The comparative effects were initially analyzed by the traditional pairwise meta-analysis method using Cochrane Collaboration review manager software (RevMan v.5.1.0). We estimated the relative risk for dichotomous outcomes and the standardized mean difference (SMD) for continuous outcomes pooled across studies by using the DerSimonian & Laird random effects model [18] . We used a 95% confidence interval (CI). If the result of analysis showed P > 0.05, we considered the studies homogeneous and so chose a fixed effect model for meta-analysis. Otherwise, a random effect model was used. We quantified inconsistency using the I 2 statistic, which describes the proportion of heterogeneity across studies that is not due to chance, thus describing the extent of true inconsistency in results across trials [19] . I 2 <25% reflects a small level of inconsistency and I 2 >50% reflects significant inconsistency.
Results
Search results and study characteristics
The literature search yielded 798 citations, of which 747 were excluded after review of titles and abstracts. The full texts of 13 remaining citations were screened, and finally eight studies [5, [20] [21] [22] [23] [24] [25] [26] including 1048 patients were included ( Figure 1 ). Of these, four studies [21] [22] [23] 25] were included to assess the efficacy and safety of silodosin in MET compared with placebo and five studies [5, 20, 23, 24, 26] were included to assess silodosin compared with tamsulosin. The baseline characteristics of the studies included in our meta-analysis are listed in Table 1 .
Quality of individual studies
All nine RCTs were double-blind and all described the randomization processes that they had used. All included a power calculation to determine the optimal sample size ( Table 2 ). The level of quality of each identified study was A to B ( Table 2 ). The funnel plot provided a qualitative estimation of publication bias of the studies, and no evidence of bias was found ( Figure 5 ).
Silodosin compared with placebo
Expulsion rate in all cases A total of two RCTs including 413 participants (204 in the silodosin group and 209 in the placebo group) (Figure 2 ) contributed to the analysis of the expulsion rate of all ureteral stones. According to our analysis, no heterogeneity was found among the trials, and a fixed effects model was thus chosen for the analysis. Compared with placebo, silodosin was associated with a significantly higher expulsion rate (OR 1.59, 95% CI 1.08, 2.36, P = 0.02). The expulsion rate in all cases with silodosin was about 8%-16% higher than with placebo.
Expulsion rate of distal ureteral stones A total of three RCTs including 279 participants (136 in the silodosin group and 143 in the placebo group) (Figure 2 ) contributed to the analysis of the expulsion rate of distal ureteral stones. Compared with placebo, silodosin was associated with a significantly higher expulsion rate (OR 2.82, 95% CI 1.70, 4.67, P < 0.0001). The expulsion rate of distal ureteral stones with silodosin ranged from 69% to 86%, which is about 24%-31% higher than with placebo.
Expulsion time (days) of distal ureteral stones A total of two RCTs including 168 participants (84 in the silodosin group and 84 in the placebo group) (Figure 3 ) contributed to the analysis of the expulsion time (days) of distal ureteral stones. Network meta-analysis demonstrated that silodosin was associated with a significant decrease in expulsion time of distal ureteral stones compared with placebo (SMD -4.71; 95% CI À6.60 to À2.83, P < 0.00001). Silodosin compared with tamsulosin Expulsion rate of distal ureteral stones A total of five RCTs including 572 participants (285 in the silodosin group and 287 in the tamsulosin group) (Figure 2 ) contributed to the analysis of the expulsion rate of distal ureteral stones.
According to our analysis, no heterogeneity was found among the trials, and a fixed effects model was thus chosen for the analysis. Compared with tamsulosin, silodosin was associated with a significantly higher expulsion rate (OR 2.54, 95% CI 1.70, 3.78, P < 0.0001). The Efficacy and safety of silodosin for calculi expulsion rate of distal ureteral stones with silodosin was about 17% higher than with tamsulosin.
Expulsion time (days) of distal ureteral stones A total of three RCTs including 339 participants (169 in the silodosin group and 170 in the tamsulosin group) (Figure 3 ) contributed to the analysis of the expulsion time (days) of distal ureteral stones. Network metaanalysis demonstrated that silodosin was associated with a significant decrease in expulsion time of distal ureteral stones compared with tamsulosin (SMD -2.64, 95% CI À3.64, À1.64, P < 0.00001). The expulsion time (days) of distal ureteral stones with silodosin was about 3 days less than with tamsulosin.
Pain episodes A total of two RCTs including 239 participants (119 in the silodosin group and 120 in the tamsulosin group) (Figure 4 ) contributed to the analysis of the pain episodes. Network meta-analysis demonstrated that silodosin was associated with a significant decrease in pain episodes compared with tamsulosin (SMD -0.55, 95% CI À0.77, À0.33, P < 0.00001).
Abnormal ejaculation A total of three RCTs including 309 participants (158 in the silodosin group and 151 in the tamsulosin group) (Figure 4 ) contributed to the analysis of the abnormal ejaculation episodes. Compared with tamsulosin, silodosin was associated with a significantly higher abnormal ejaculation episodes (OR 2.47, 95% CI 1.20, 5.07, P = 0.01).
Complications A total of two RCTs including 226 participants (114 in the silodosin group and 112 in the tamsulosin group) (Figure 4 ) contributed to the analysis of the complication episodes. The adverse events caused by silodosin were generally mild and did not require cessation of therapy in any patient. Dizziness, postural hypotension, headache, nasal congestion, backache, diarrhoea and abnormal ejaculation were the most common reported adverse events. Based on our analysis, the pooled estimate of OR was 1.00 and the 95% CI was 0.58, 1.74 (P = 1.00). This result suggests that silodosin showed no significant difference in complication episodes compared with tamsulosin ( Figure 5 ).
Discussion
Ureteral colic, which is mainly due to ureterolithiasis, represents 1 to 2% of the hospital emergency admissions. MET has recently emerged as an alternative strategy for Figure 4 (A) changes in pain episodes and (B) changes in abnormal ejaculation and the total complication Efficacy and safety of silodosin for calculi the initial management of selected patients with distal ureteric stones [27] . The role of adrenergic receptors in the human ureter was first described in 1970 [28] . It was shown that the α-adrenergic receptor agonists had a stimulatory effect on the ureteral smooth muscle, whereas the α-adrenergic receptor agonists had an inhibitory effect [29] . They prevent the uncoordinated muscle activity which is seen in renal colic, while maintaining ureteral peristalsis, which might facilitate a spontaneous stone passage [27] . The α-adrenoceptor blockers mainly produce relaxation of the distal human ureter by reducing the ureteric smooth muscle tone rather than completely ablating its activity. In 2005, Sigala et al.
found that α 1D -and α 1A -adrenoceptors were expressed in significantly larger amounts than α 1B -adrenoceptors in the human ureter [27] . These authors also demonstrated that the distal ureter expressed a greater amount of α 1 -adrenoceptor mRNA than the proximal and medial ureter. Itoh et al. reported that α 1D -adrenoceptor mRNA is more highly expressed than α 1A -adrenoceptor mRNA in each region of the ureter [30] . It was shown that the α-adrenergic receptors were classified into three different subtypes of α 1A , α 1B and α 1D , of which the distribution in the human ureter was α 1D >α 1A >α 1B (Table 3 ) [30] . According to their results, an α 1D -adrenoceptor blocker maybe expected to be more effective for the expulsion of ureteral stones than an α 1A -adrenoceptor blocker. However, Tomiyama et al. reported that, in the hamster ureter, ureteral contraction was mediated mainly by α 1A -adrenoceptors, even though α 1D -adrenoceptors were more prevalent [31] . Besides, Tsuzaka et al. reported that an α 1A -adrenoceptor blocker was more effective than an α 1D -adrenoceptor blocker with respect to stone expulsion rate, suggesting more clinical usefulness of α 1A -adrenoceptor blockers [16] . Sasaki et al. found that among α 1 -adrenoceptors, the α 1A subtype played the major role in contraction in the human ureter [15] . Accordingly, α 1A -adrenoceptor antagonists could become a useful medication for stone passage in urolithiasis patients. We speculate that α 1A -adrenoceptors and α 1D -adrenoceptors both have effect on the contraction in the human ureter and the selectivity of drugs with different α 1 -receptor subtypes is different (Table 4A ) [32] [33] [34] .
In Table 4A , we set at 1 for α 1B subtype in order to compare the selectivity of drugs with α 1A subtype and α 1D subtype, but in reality they are all different. In addition, the binding affinities (pKi) for various α 1 adrenergic receptor antagonists at α 1 -adrenergic receptor subtypes is also different (Table 4B) , which is a composite from different studies [32] [33] [34] . Tamsulosin, which is a selective α 1A /α 1D -adrenergic receptor antagonist, has been widely studied in the context of MET for patients with distal ureteric stones smaller than 10 mm. It has been proved that tamsulosin increases stone expulsion rates, decreases pain, reduces mean time to stone expulsion and decreases analgesic usage when compared with placebo [35] [36] [37] [38] [39] . Although most of the studies used tamsulosin, the efficacies of the other α-adrenoceptor blockers such as doxazosin, terazosin, alfuzosin and naftopidil were also indicated Table 4B Binding affinities (pKi) for various α 1 -adrenoceptor (AR) antagonists at α 1 -AR subtypes [32] [33] [34] Figure 5 Funnel plot of the studies represented in our meta-analysis Table 3 Distribution of α 1 -adrenoceptor (AR) subtypes in the the body's tissues [30] Ureteral Urethral Vascular Table 4A ). In other words, silodosin has a higher affinity for the α 1A subtype than tamsulosin (10.5 vs. 9. 2 Table 5B ). Then, will silodosin have a greater effect on MET than tamsulosin? Our study reveals that silodosin was effective in the expulsion rate of all ureteral stones, in the expulsion rate of distal ureteral stones and in the expulsion time of distal ureteral stones compared with placebo. We found the expulsion rate of silodosin was 74.3% in the distal ureter, which was approximately 24% higher with silodosin than placebo. Itoh et al. [22] reported that there was no significant difference in expulsion rate of stones <5 mm between silodosin and placebo. We assumed that maybe because of the high likelihood of spontaneous passage for stones up to approximately 5 mm, MET is less likely to increase the stone-free rate because of the high spontaneous expulsion rate [43] . Therefore, it is important that administration of silodosin can facilitate expulsion of 5-10 mm distal ureteral stones, as compared with control. Our study also reveals that silodosin was more effective than tamsulosin in the expulsion rate of distal ureteral stones, in the expulsion time and in pain episodes. Stone expulsion rate in patients with distal ureteric stones treated with silodosin was 83.5% with a mean expulsion time of 11 days, which was superior to tamsulosin (66.9%, 14 days). The results of this study indicated that silodosin increases distal ureteric stone expulsion significantly along with better control of pain [5] .
Adverse side effects commonly reported with different α 1 -adrenoceptor blockers include dizziness, headache, asthenia, postural hypotension, syncope, rhinitis and sexual dysfunction [44, 45] . Even though silodosin has a higher incidence of abnormal ejaculation than tamsulosin, no significant difference was observed in the incidence of total adverse events. Besides, we found that retrograde ejaculation were mild to moderate and was well tolerated. Those patients who experienced a retrograde ejaculation were followed-up and they were found to have been relieved of this problem [24] . No side-effects that required cessation of the treatment with silodosin were encountered.
As the dose of silodosin was 8 mg daily, so we can conclude that silodosin 8 mg daily is an effective and well tolerated treatment for ureteral calculi. MET should be offered as a cost-effective treatment for the patients with distal ureteral calculi sized 10 mm or smaller, who are amenable to a waiting management.
This meta-analysis includes studies which are all findings from randomized double-blind, placebo-controlled trials. According to the quality assessment scale that we developed, the quality of the individual studies in the meta-analysis was conforming. The results of this analysis have great importance from the scientific standpoint but also in everyday clinical practice. However the number of included studies was not many. The longer term safety, efficacy and persistence of silodosin cannot be extrapolated from this article. In addition, data from unpublished studies were not included in the analysis. These factors may have resulted in a bias. More high quality trials with larger samples are proposed to learn more about the efficacy and safety of the therapy on ureteral calculi. Further studies on MET for ureteral stones are needed to determine the superiority of α 1A -vs. α 1D -adrenoceptor blockers.
Conclusion
This meta-analysis indicates that silodosin was superior to placebo or tamsulosin in its efficacy for distal ureteral calculi with better control of pain. The safety profile of silodosin was similar to tamsulosin though retrograde ejaculation was worse with silodosin use. We conclude that silodosin might have potential as a MET for ureteral stones.
